{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:26Z","timestamp":1792783466406,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"EU Horizon 2020 research and innovation program","award":["739593"],"award-info":[{"award-number":["739593"]}]},{"name":"Hungarian Centre of Excellence for Molecular Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13555-025-01397-z","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T02:40:49Z","timestamp":1746585649000},"page":"1657-1679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and Safety of JAK Inhibitors in the Management of Vitiligo: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8719-4412","authenticated-orcid":false,"given":"Alzahra A.","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.","family":"Lengyel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanni A.","family":"Meznerics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Szondy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bence","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorottya","family":"P\u00e1l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienn","family":"Bojtor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"B\u00e1nv\u00f6lgyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Hegyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos V.","family":"Kem\u00e9ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Kurgyis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"10","key":"1397_CR1","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","volume":"51","author":"C Kruger","year":"2012","unstructured":"Kruger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children\/adolescents and adults. Int J Dermatol. 2012;51(10):1206\u201312.","journal-title":"Int J Dermatol"},{"key":"1397_CR2","first-page":"327","volume":"11","author":"M Al-Harbi","year":"2013","unstructured":"Al-Harbi M. Prevalence of depression in vitiligo patients. Skinmed. 2013;11:327\u201330.","journal-title":"Skinmed"},{"issue":"2","key":"1397_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.det.2016.11.013","volume":"35","author":"RA Spritz","year":"2017","unstructured":"Spritz RA. Genetics of vitiligo. Dermatol Clin. 2017;35(2):245\u201355.","journal-title":"Dermatol Clin"},{"issue":"3","key":"1397_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jdermsci.2023.12.008","volume":"113","author":"S Inoue","year":"2024","unstructured":"Inoue S. JAK inhibitors for the treatment of vitiligo. J Dermatol Sci. 2024;113(3):86\u201392.","journal-title":"J Dermatol Sci"},{"key":"1397_CR5","doi-asserted-by":"publisher","first-page":"15011","DOI":"10.1038\/nrdp.2015.11","volume":"1","author":"M Picardo","year":"2015","unstructured":"Picardo M. Vitiligo. Nat Rev Dis Primers. 2015;1:15011.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1397_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3892\/etm.2021.10229","volume":"22","author":"DE Kubelis-Lopez","year":"2021","unstructured":"Kubelis-Lopez DE. Updates and new medical treatments for vitiligo (review). Exp Ther Med. 2021;22(2):797.","journal-title":"Exp Ther Med"},{"key":"1397_CR7","doi-asserted-by":"crossref","unstructured":"Views on vitiligo disease course and treatment among people living with vitiligo and healthcare providers worldwide. Br J Dermatol. 2023;189:e94.","DOI":"10.1093\/bjd\/ljad350"},{"issue":"2","key":"1397_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1046\/j.1523-1747.2001.01408.x","volume":"117","author":"B Palermo","year":"2001","unstructured":"Palermo B. Specific cytotoxic T lymphocyte responses against Melan-A\/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex\/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol. 2001;117(2):326\u201332.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1397_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2016.12.021","volume":"76","author":"JP Strassner","year":"2017","unstructured":"Strassner JP. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J Am Acad Dermatol. 2017;76(5):847-855.e5.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1397_CR10","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/jid.2009.32","volume":"129","author":"JG van den Boorn","year":"2009","unstructured":"van den Boorn JG. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol. 2009;129(9):2220\u201332.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1397_CR11","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/01.LAB.0000069521.42488.1B","volume":"83","author":"A Wankowicz-Kalinska","year":"2003","unstructured":"Wankowicz-Kalinska A. Immunopolarization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest. 2003;83(5):683\u201395.","journal-title":"Lab Invest"},{"key":"1397_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125","volume":"12","author":"F Qi","year":"2021","unstructured":"Qi F. Janus kinase inhibitors in the treatment of vitiligo: a review. Front Immunol. 2021;12: 790125.","journal-title":"Front Immunol"},{"key":"1397_CR13","volume":"81","author":"A Sheikh","year":"2022","unstructured":"Sheikh A. FDA approves Ruxolitinib (Opzelura) for vitiligo therapy: a breakthrough in the field of dermatology. Ann Med Surg (Lond). 2022;81: 104499.","journal-title":"Ann Med Surg (Lond)"},{"key":"1397_CR14","unstructured":"Hurrell A. Nice Ruxolitinib (Opzelura) appraisal update (May 2024): Vitiligo Society; 2024. https:\/\/vitiligosociety.org\/vitlife\/nice-ruxolitinib-appraisal-update\/."},{"issue":"11","key":"1397_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"key":"1397_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et\u00a0al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"issue":"6","key":"1397_CR17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archderm.140.6.677","volume":"140","author":"I Hamzavi","year":"2004","unstructured":"Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the vitiligo area scoring index. Arch Dermatol. 2004;140(6):677\u201383.","journal-title":"Arch Dermatol"},{"issue":"29","key":"1397_CR18","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1002\/sim.4040","volume":"29","author":"T Stijnen","year":"2010","unstructured":"Stijnen T. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med. 2010;29(29):3046\u201367.","journal-title":"Stat Med"},{"key":"1397_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1348","author":"G Schwarzer","year":"2019","unstructured":"Schwarzer G. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods. 2019. https:\/\/doi.org\/10.1002\/jrsm.1348.","journal-title":"Res Synth Methods"},{"issue":"4","key":"1397_CR20","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719\u201348.","journal-title":"J Natl Cancer Inst"},{"key":"1397_CR21","doi-asserted-by":"publisher","DOI":"10.2307\/2331986","author":"CJ Clopper","year":"1934","unstructured":"Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934. https:\/\/doi.org\/10.2307\/2331986.","journal-title":"Biometrika"},{"key":"1397_CR22","volume-title":"The handbook of research synthesis and meta-analysis","author":"HM Cooper","year":"2009","unstructured":"Cooper HM, Hedges LV, Valentine JC. The handbook of research synthesis and meta-analysis. 2nd ed. New York: Russell Sage Foundation; 2009.","edition":"2"},{"key":"1397_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25.","journal-title":"BMC Med Res Methodol"},{"issue":"17","key":"1397_CR24","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/sim.1482","volume":"22","author":"G Knapp","year":"2003","unstructured":"Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003;22(17):2693\u2013710.","journal-title":"Stat Med"},{"issue":"1","key":"1397_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","volume":"7","author":"AA Veroniki","year":"2016","unstructured":"Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et\u00a0al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7(1):55\u201379.","journal-title":"Res Synth Methods"},{"key":"1397_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.6028\/jres.087.022","volume":"85","author":"R Paule","year":"1982","unstructured":"Paule R, Mandel J. Consensus values and weighting factors. J Res Natl Bureau Standards. 1982;85:377\u201387.","journal-title":"J Res Natl Bureau Standards"},{"issue":"16","key":"1397_CR27","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445\u201355.","journal-title":"N Engl J Med"},{"issue":"6","key":"1397_CR28","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"78","author":"D Rosmarin","year":"2020","unstructured":"Rosmarin D. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;78(6):1205\u20137.e1201. https:\/\/doi.org\/10.1016\/S0140-6736(20)30609-7.","journal-title":"Lancet"},{"issue":"6","key":"1397_CR29","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jaad.2023.07.1016","volume":"89","author":"X Su","year":"2023","unstructured":"Su X, Luo R, Ruan S, Zhong Q, Zhuang Z, Xiao Z, et\u00a0al. Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo. J Am Acad Dermatol. 2023;89(6):1257\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1397_CR30","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","volume":"76","author":"B Rothstein","year":"2017","unstructured":"Rothstein B. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017;76(6):1054-60.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1397_CR31","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jaad.2019.04.032","volume":"81","author":"J McKesey","year":"2019","unstructured":"McKesey J. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo. J Am Acad Dermatol. 2019;81(2):646\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1397_CR32","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.18606","volume":"182","author":"P Mobasher","year":"2020","unstructured":"Mobasher P. Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo. Br J Dermatol. 2020;182(4):1047\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1397_CR33","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","volume":"74","author":"JE Harris","year":"2016","unstructured":"Harris JE. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016;74(2):370\u20131.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1397_CR34","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","volume":"77","author":"LY Liu","year":"2017","unstructured":"Liu LY. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017;77(4):675-82.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1397_CR35","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","volume":"154","author":"SR Kim","year":"2018","unstructured":"Kim SR. Rapid repigmentation of vitiligo using tofacitinib plus low-dose, narrowband UV-B phototherapy. JAMA Dermatol. 2018;154(3):370\u20131.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1397_CR36","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.abd.2019.08.032","volume":"95","author":"M Komnitski","year":"2020","unstructured":"Komnitski M. Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation. An Bras Dermatol. 2020;95(4):473\u20136.","journal-title":"An Bras Dermatol"},{"issue":"4","key":"1397_CR37","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/ajd.13348","volume":"61","author":"BP Mumford","year":"2020","unstructured":"Mumford BP. Repigmentation of vitiligo with oral baricitinib. Australas J Dermatol. 2020;61(4):374\u20136.","journal-title":"Australas J Dermatol"},{"issue":"1","key":"1397_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5152\/eurjrheum.2020.20007","volume":"8","author":"M Scheinberg","year":"2021","unstructured":"Scheinberg M. Tofacitinib-induced remission simultaneously in arthritis and vitiligo. Eur J Rheumatol. 2021;8(1):55\u20136.","journal-title":"Eur J Rheumatol"},{"issue":"2","key":"1397_CR39","doi-asserted-by":"publisher","first-page":"155932582211053","DOI":"10.1177\/15593258221105370","volume":"20","author":"J Dong","year":"2022","unstructured":"Dong J. Baricitinib is effective in treating progressing vitiligo in vivo and in vitro. Dose Response. 2022;20(2):15593258221105370.","journal-title":"Dose Response"},{"issue":"5","key":"1397_CR40","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/ccr3.2759","volume":"8","author":"M Tajalli","year":"2020","unstructured":"Tajalli M, Kabir S, Vance TM, Qureshi AA. Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vitiligo, and plaque and inverse psoriasis. Clin Case Rep. 2020;8(5):819\u201322.","journal-title":"Clin Case Rep"},{"key":"1397_CR41","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jdcr.2022.02.025","volume":"23","author":"AY Moore","year":"2022","unstructured":"Moore AY. Amelioration of unstable vitiligo and normalization of thryroglobulin antibodies with oral tofacitinib. JAAD Case Rep. 2022;23:64\u20136.","journal-title":"JAAD Case Rep"},{"key":"1397_CR42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.2147\/CCID.S396430","volume":"16","author":"X Li","year":"2023","unstructured":"Li X. Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB-UVB phototherapy. Clin Cosmet Investig Dermatol. 2023;16:635\u20138.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"1397_CR43","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/ced.15070","volume":"47","author":"WC Fang","year":"2022","unstructured":"Fang WC. Low-dose tofacitinib with 308-nm excimer therapy successfully induced repigmentation in patients with refractory vitiligo. Clin Exp Dermatol. 2022;47(4):782\u20133.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1397_CR44","doi-asserted-by":"publisher","first-page":"2200873","DOI":"10.1080\/09546634.2023.2200873","volume":"34","author":"T Pan","year":"2023","unstructured":"Pan T. Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report. J Dermatolog Treat. 2023;34(1):2200873.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1397_CR45","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","volume":"88","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine K. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial. J Am Acad Dermatol. 2023;88(2):395\u2013403.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1397_CR46","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/phpp.12661","volume":"37","author":"WC Fang","year":"2021","unstructured":"Fang WC. Evaluation of low-dose tofacitinib combining narrowband UVB therapy for treating vitiligo patients who had failed previous therapy: a pilot study. Photodermatol Photoimmunol Photomed. 2021;37(4):345\u20137.","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"6","key":"1397_CR47","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jaad.2018.02.023","volume":"78","author":"D Joshipura","year":"2018","unstructured":"Joshipura D. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B. J Am Acad Dermatol. 2018;78(6):1205-7.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1397_CR48","volume":"35","author":"H Song","year":"2022","unstructured":"Song H. Effectiveness and safety of tofacitinib combined with narrowband ultraviolet B phototherapy for patients with refractory vitiligo in real-world clinical practice. Dermatol Ther. 2022;35(1): e15821.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1397_CR49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3889\/oamjms.2018.042","volume":"6","author":"S Gianfaldoni","year":"2018","unstructured":"Gianfaldoni S. Micro-focused phototherapy associated to Janus kinase inhibitor: a promising valid therapeutic option for patients with localized vitiligo. Open Access Maced J Med Sci. 2018;6(1):46\u20138.","journal-title":"Open Access Maced J Med Sci"},{"issue":"4","key":"1397_CR50","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1684\/ejd.2023.4513","volume":"33","author":"K Murakami","year":"2023","unstructured":"Murakami K. Successful management of severe alopecia areata and vitiligo using topical delgocitinib and a 308-nm excimer laser. Eur J Dermatol. 2023;33(4):428\u201330.","journal-title":"Eur J Dermatol"},{"key":"1397_CR51","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002461","volume":"40","author":"MB Camacho","year":"2024","unstructured":"Camacho MB. Eyelid vitiligo treatment with topical ruxolitinib. Ophthalmic Plast Reconstr Surg. 2024;40: e70.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"6","key":"1397_CR52","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1111\/ijd.16323","volume":"62","author":"DJ Aickara","year":"2023","unstructured":"Aickara DJ, Patel S, Rosen J, Alonso-Llamazares J. Significant improvement of vitiligo with oral tofacitinib treatment. Int J Dermatol. 2023;62(6):e358\u201360.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1397_CR53","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/ajd.13572","volume":"62","author":"K Yagi","year":"2021","unstructured":"Yagi K, Ishida Y, Otsuka A, Kabashima K. Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib. Australas J Dermatol. 2021;62(3):433\u20134.","journal-title":"Australas J Dermatol"},{"key":"1397_CR54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000513938","volume":"13","author":"FS Berbert","year":"2021","unstructured":"Berbert FS. Topical tofacitinib: a Janus kinase inhibitor for the treatment of vitiligo in an adolescent patient. Case Rep Dermatol. 2021;13:190\u20134.","journal-title":"Case Rep Dermatol"},{"issue":"4","key":"1397_CR55","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/pde.14159","volume":"37","author":"B Olamiju","year":"2020","unstructured":"Olamiju B. Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child. Pediatr Dermatol. 2020;37(4):754\u20135.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"1397_CR56","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/09546634.2017.1339013","volume":"29","author":"D Joshipura","year":"2018","unstructured":"Joshipura D. Importance of light in the treatment of vitiligo with JAK-inhibitors. J Dermatolog Treat. 2018;29(1):98\u20139.","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"1397_CR57","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/ced.13672","volume":"43","author":"WT Hu","year":"2018","unstructured":"Hu WT, Lin FQ, Xu AE. Treatment of halo naevus with the topical Janus kinase inhibitor tofacitinib 1.5. Clin Exp Dermatol. 2018;43(8):935\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"1397_CR58","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/ced.13290","volume":"42","author":"M Vu","year":"2017","unstructured":"Vu M. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo. Clin Exp Dermatol. 2017;42(8):942\u20134.","journal-title":"Clin Exp Dermatol"},{"issue":"23","key":"1397_CR59","first-page":"2897","volume":"136","author":"X Huang","year":"2023","unstructured":"Huang X. Jak inhibitors in vitiligo: a meta analysis. Chin Med J (Engl). 2023;136(23):2897\u20138.","journal-title":"Chin Med J (Engl)"},{"key":"1397_CR60","unstructured":"AbbVie announces Upadacitinib (RINVOQ\u00ae) met the primary endpoint in phase 2 clinical trial of vitiligo as program advances to phase 3. AbbVie News Center; 2023. https:\/\/news.abbvie.com\/2023-10-12-AbbVie-Announces-Upadacitinib-RINVOQ-R-Met-the-Primary-Endpoint-in-Phase-2-Clinical-Trial-of-Vitiligo-as-Program-Advances-to-Phase-3."},{"issue":"3","key":"1397_CR61","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","volume":"13","author":"C Samuel","year":"2023","unstructured":"Samuel C. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023;13(3):729\u201349.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1397_CR62","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/09546634.2020.1735615","volume":"33","author":"K Phan","year":"2022","unstructured":"Phan K. Repigmentation in vitiligo using Janus kinase (JAK) inhibitors with phototherapy: systematic review and meta-analysis. J Dermatol Treat. 2022;33(1):173\u20137.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"1397_CR63","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaad.2015.05.038","volume":"73","author":"EW Mu","year":"2015","unstructured":"Mu EW. Early-onset childhood vitiligo is associated with a more extensive and progressive course. J Am Acad Dermatol. 2015;73(3):467\u201370.","journal-title":"J Am Acad Dermatol"},{"key":"1397_CR64","doi-asserted-by":"publisher","DOI":"10.5070\/D329260765","author":"S Cruz","year":"2023","unstructured":"Cruz S. The psychosocial impacts of vitiligo, psoriasis, and alopecia areata on pediatric patients. Dermatol Online J. 2023. https:\/\/doi.org\/10.5070\/D329260765.","journal-title":"Dermatol Online J"},{"key":"1397_CR65","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1055\/s-0043-121201","volume":"44","author":"A Tanew","year":"2018","unstructured":"Tanew A. Phototherapie bei p\u00e4diatrischen Hautkrankheiten. Aktuelle Dermatol. 2018;44:24\u20139.","journal-title":"Aktuelle Dermatol"},{"issue":"4","key":"1397_CR66","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jamadermatol.2024.0021","volume":"160","author":"Y Renert-Yuval","year":"2024","unstructured":"Renert-Yuval Y. Expert recommendations on use of topical therapeutics for vitiligo in pediatric, adolescent, and young adult patients. JAMA Dermatol. 2024;160(4):453\u201361.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"1397_CR67","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s13555-022-00752-8","volume":"12","author":"H Kitchen","year":"2022","unstructured":"Kitchen H. Meaningful changes in what matters to individuals with vitiligo: content validity and meaningful change thresholds of the vitiligo area scoring index (VASI). Dermatol Ther (Heidelb). 2022;12(7):1623\u201337.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"1397_CR68","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41591-021-01458-8","volume":"27","author":"P Hegyi","year":"2021","unstructured":"Hegyi P. Accelerating the translational medicine cycle: the Academia Europaea pilot. Nat Med. 2021;27(8):1317\u20139.","journal-title":"Nat Med"},{"issue":"5","key":"1397_CR69","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3390\/jcm9051532","volume":"9","author":"P Hegyi","year":"2020","unstructured":"Hegyi P. Academia Europaea position paper on translational medicine: the cycle model for translating scientific results into community benefits. J Clin Med. 2020;9(5):1532.","journal-title":"J Clin Med"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01397-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01397-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01397-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T07:03:07Z","timestamp":1748674987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01397-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1397"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01397-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alzahra Ahmed Mohammed, Anna S\u00e1ra Lengyel, Fanni Ad\u00e9l Meznerics, Istv\u00e1n Szondy, Anna Walter, Bence Szab\u00f3, Dorottya P\u00e1l, Adrienn Bojtor, Andr\u00e1s B\u00e1nv\u00f6lgyi, Norbert Kiss, P\u00e9ter Hegyi, Zsuzsanna Kurgyis and Lajos Vince Kem\u00e9ny have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No ethical approval was required for this study as all data were sourced from peer-reviewed journals. No patients were involved in the design, conduct or interpretation of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}